Medical Educational Resource
We're accelerating the delivery of treatments and cures.
Interim analysis from ongoing Phase 3 FORTIFY study of BBP-418 for patients with limb girdle muscular dystrophy 2I/R9 meets efficacy endpoints
Activity Snapshot
Activity Type:
Live, Virtual Webinar
Release Date:
Tuesday, May 19, 2026
Sponsor Information:
Activity Overview:
Dr. Doug Sproule, Chief Medical Officer of Bridge Bio, will discuss the interim analysis from ongoing Phase 3 FORTIFY study of BBP-418 for patients with limb girdle muscular dystrophy 2I/R9.
If you have questions or comments, contact mdapartners@mdausa.org. For more educational programs and resources for medical professionals, please visit mda.org/meded.
